Spyre Therapeutics, Inc. SYRE Derivative Liabilities - Fair Value
Derivative Liabilities - Fair Value at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DerivativeLiabilitiesCurrent.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s derivative liabilities - fair value.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s derivative liabilities - fair value?
- Spyre Therapeutics, Inc. (SYRE) reported derivative liabilities - fair value of $50.26M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s derivative liabilities - fair value changed year-over-year?
- Spyre Therapeutics, Inc.'s derivative liabilities - fair value increased by 17.4% year-over-year, from $42.81M to $50.26M.
- What does derivative liabilities - fair value mean?
- The current value of financial contracts that the company owes and must settle within one year.
- How do you interpret derivative liabilities - fair value?
- A decrease is generally favorable as it reduces short-term financial obligations, while an increase may signal rising costs associated with financing instruments.
- How does derivative liabilities - fair value compare across companies?
- Common in companies with complex capital structures or those utilizing warrants and other equity-linked derivatives.